X

Trial Profile

A retrospective cohort study assessing the real world effectiveness of Benralizumab on Asthma exacerbations

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Asthma
Focus Therapeutic Use
Acronyms ZEPHYR 1

Most Recent Events

05 Apr 2022 According to a Analysis Group Media Release, Fan Mu is the study investigator
05 Apr 2022 Results published in the Analysis Group Media Release
02 Mar 2022 Results characterizing patients with severe asthma treated with benralizumab and assess its clinical and economic impact in the USpublished in the Annals of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com